Intestinal
and hepatic glucuronidation by the UDP-glucuronosyltransferases
(UGTs) greatly affect the bioavailability of phenolic compounds. UGT1A10
catalyzes glucuronidation reactions in the intestine, but not in the
liver. Here, our aim was to develop selective, fluorescent substrates
to easily elucidate UGT1A10 function. To this end, homology models
were constructed and used to design new substrates, and subsequently,
six novel C3-substituted (4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl,
4-(dimethylamino)phenyl, 4-methylphenyl, or triazole) 7-hydroxycoumarin
derivatives were synthesized from inexpensive starting materials.
All tested compounds could be glucuronidated to nonfluorescent glucuronides
by UGT1A10, four of them highly selectively by this enzyme. A new
UGT1A10 mutant, 1A10-H210M, was prepared on the basis of the newly
constructed model. Glucuronidation kinetics of the new compounds,
in both wild-type and mutant UGT1A10 enzymes, revealed variable effects
of the mutation. All six new C3-substituted 7-hydroxycoumarins were
glucuronidated faster by human intestine than by liver microsomes,
supporting the results obtained with recombinant UGTs. The most selective
4-(dimethylamino)phenyl and triazole C3-substituted 7-hydroxycoumarins
could be very useful substrates in studying the function and expression
of the human UGT1A10.